Company news

Replimune Group, Inc. news in 2026

Replimune Group, Inc.'s news releases, calls and decks from 2026, newest first.

View company

Replimune Reports Fiscal Second Quarter 2027 Financial Results and Provides Corporate Update

October 28, 2026

Replimune to Report the Fiscal Second Quarter 2027 Financial Results and Provide Corporate Update on October 28, 2026

October 22, 2026

Replimune Announces TUDRIQEV™ Now Available in the U.S. for Advanced Melanoma

October 1, 2026

Replimune to Present at the Cantor Global Healthcare Conference 2026

September 3, 2026

Replimune Reports Fiscal First Quarter 2027 Financial Results and Provides Corporate Update

August 14, 2026

Replimune Announces Pricing of $150 Million Underwritten Offering

August 10, 2026

Replimune Announces FDA Accelerated Approval of TUDRIQEVTM in Combination with Nivolumab for Unresectable Advanced Cutaneous Melanoma After Progression on an anti-PD-1 Based Regimen

August 6, 2026

Replimune Announces Favorable Outcome of FDA's Cellular, Tissue, and Gene Therapies Advisory Committee Meeting for RP1 in Advanced Melanoma

July 30, 2026

Replimune Reports Fiscal Fourth Quarter and Year End 2026 Financial Results and Provides Corporate Update

June 29, 2026

Replimune Announces FDA Acceptance of RP1 Biologics License Application Resubmission for Advanced Melanoma

June 26, 2026

Replimune Presents Final First-in-Human Data for RP2 in Advanced Solid Tumors During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting

May 31, 2026

Replimune Presents 3-Year Landmark Overall Survival Analysis from IGNYTE Clinical Trial During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting

May 29, 2026

Replimune Announces Planned RP1 BLA Resubmission Following Productive Discussion with FDA

May 29, 2026

Replimune to Present at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting

April 27, 2026

Replimune Reports Fiscal Third Quarter 2026 Financial Results and Provides Corporate Update

February 2, 2026

Calls in 2026

Decks in 2026